Weight loss drugs like Ozempic can raise low testosterone — what that means for men
Testosterone fuels male sex drive and erectile function and influences everything from bone density and muscle mass to fat distribution, red blood cell production, mood and energy levels.
Unfortunately, testosterone levels naturally decline with age. Older men may feel more tired and grouchy and less interested in sex. Not to mention the hair loss, bone fractures and weight gain around the waist that often accompany low T.
Advertisement
3 Testosterone levels significantly affect a man's physical, sexual and mental well-being.
AntonioDiaz – stock.adobe.com
Luckily, there are ways to naturally boost testosterone. Exercise, especially strength training, a healthy diet, stress reduction, adequate sleep and weight management, particularly for those who are overweight, are just a few.
A new study highlights another tool that may help elevate these levels — Ozempic and other GLP-1 drugs.
Advertisement
Research indicates that weight loss can enhance testosterone levels because excess body fat contains the enzyme aromatase, which converts testosterone into estrogen.
'While it is well-known that weight loss from lifestyle changes or bariatric surgery increases testosterone levels, the impact that anti-obesity medications may also have on these levels has not been widely studied,' said Dr. Shellsea Portillo Canales, an endocrinology fellow at SSM Health St. Louis University Hospital in Missouri.
'Our study is among the first to provide compelling evidence that low testosterone can be reversed with the use of commonly prescribed anti-obesity medications.'
3 Ozempic and other GLP-1 drugs may help elevate testosterone levels through weight loss.
mbruxelle – stock.adobe.com
Advertisement
Portillo Canales' team analyzed the records of 110 adult men with obesity or Type 2 diabetes taking the weight-loss medications semaglutide (Wegovy), dulaglutide (Trulicity) or tirzepatide (Zepbound) but not participating in testosterone or hormonal therapy.
These three drugs mimic the effects of GLP-1, a natural hormone in the body that regulates blood sugar and appetite, often leading to lower blood sugar and weight loss.
On average, the participants experienced 10% weight loss and saw their testosterone levels rise from 53% to 77% over 18 months.
Advertisement
Weight loss improves insulin sensitivity, reduces inflammation and lowers aromatase activity, which contribute to increased testosterone production.
The findings were presented Monday at ENDO 2025, the Endocrine Society's meeting in San Francisco.
'Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,' said Portillo Canales.
'Doctors and their patients can now consider this class of medications not only for the treatment of obesity and to control blood sugar, but also to benefit men's reproductive health.'
3 It's important to keep an eye on testosterone levels, which naturally decline with age.
Larisa – stock.adobe.com
GLP-1 drugs are not without risks, though. Nausea, vomiting and diarrhea are among the most commonly reported side effects.
Inflammation of the pancreas, vision changes, stomach paralysis and even death are rare but serious concerns.
Advertisement
In the 20 years since the first GLP-1 drug was approved to treat diabetes, researchers have been exploring other uses for these popular meds.
Research continues on their potential to slow the progression of Alzheimer's disease, improve sleep apnea, reduce alcohol cravings and treat liver disease, among other conditions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
33 minutes ago
- UPI
GLP-1 drugs increase risk of acid reflux, GERD, study finds
People with type 2 diabetes were more likely to suffer from gastroesophageal reflux disease if they were prescribed a GLP-1 drug compared to those taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors, researchers reported Tuesday in the Annals of Internal Medicine. Photo by Robystarm/ Pixabay July 14 (UPI) -- Folks using GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, a new study says. People with type 2 diabetes were more likely to suffer from gastroesophageal reflux disease (GERD) if they were prescribed a GLP-1 drug compared to those taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors, researchers reported Tuesday in the Annals of Internal Medicine. "We estimated that most GLP-1 [drugs] increased risk for GERD," concluded the research team led by Laurent Azoulay, an associate professor with the Jewish General Hospital's Center for Clinical Epidemiology in Montreal, Canada. The risk for serious GERD-related complications was higher among smokers, people with obesity and folks with existing stomach problems, researchers said. "Although our findings need to be corroborated in other studies, clinicians and patients should be aware of a possible adverse effect of GLP-1 [drugs] on GERD," researchers noted. For the study, researchers tracked more than 24,700 type 2 diabetics newly prescribed GLP-1 drugs, comparing their health to that of more than 89,000 who were prescribed SGLT-2 inhibitors. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. Because the drugs slow the rate at which food passes through the stomach, researchers thought they might increase the risk of acid reflux. GERD occurs when acid reflux happens repeatedly over time, the Mayo Clinic says. If it continues, GERD can cause scarring and narrowing of the esophagus and increase a person's risk of esophageal cancer. Results show that people taking GLP-1 drugs were 27% more likely to develop GERD and 55% more likely to have GERD complications, when compared to people taking SGLT-2 inhibitors. More than 90% of GERD complications involved Barrett esophagus, in which acid damage changes the tissue lining of the esophagus and increases cancer risk, researchers noted. "We also found that the risk for GERD was higher with long-acting GLP-1 (drug) use," researchers wrote. However, they noted that these findings need to be verified by studies involving other groups, including those taking GLP-1 drugs for obesity. "There is limited evidence on the risk for GERD among patients with obesity who do not have type 2 diabetes," researchers wrote. "Use of GLP-1 [drugs] is rapidly expanding in this population, highlighting an important area for future research." More information The Mayo Clinic has more on GERD. Copyright © 2025 HealthDay. All rights reserved.
Business Upturn
an hour ago
- Business Upturn
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms
By GlobeNewswire Published on July 15, 2025, 22:00 IST New York, USA, July 15, 2025 (GLOBE NEWSWIRE) — Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, along with advancements in targeted therapies and early diagnostic tools, are key factors driving market growth. DelveInsight's 'Endometrial Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline endometrial cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the endometrial cancer pipeline domain. Key Takeaways from the Endometrial Cancer Pipeline Report DelveInsight's endometrial cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline endometrial cancer drugs. active players working to develop pipeline endometrial cancer drugs. Key endometrial cancer companies such as Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics , Leap Therapeutics , Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imvax, and others are evaluating new endometrial cancer drugs to improve the treatment landscape. and others are evaluating new endometrial cancer drugs to improve the treatment landscape. Promising pipeline endometrial cancer therapies, such as Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others, are in different phases of endometrial cancer clinical trials. and others, are in different phases of endometrial cancer clinical trials. In June 2025, Daiichi Sankyo announced the first patient had been dosed in the DESTINY-Endometrial01 clinical trial evaluating Enhertu (trastuzumab deruxtecan) in combination with rilvegostomig or Merck's Keytruda (pembrolizumab) as a first-line treatment for patients with HER2-expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer. In May 2025, Kaida BioPharma announced it had entered into a manufacturing agreement with Northway Biotech, Inc., an end-to-end biologics Contract Development and Manufacturing Organization (CDMO), for the manufacturing of lead product candidate, a novel biologic prolactin receptor antagonist, is being initially developed for the treatment of platinum-resistant ovarian cancer (PROC) with expansion opportunities into endometrial, uterine, and breast cancers. In May 2025, PRISM BioLab, Co. Ltd. announced that the analysis of a combination study of E7386 created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797), expansion cohort of advanced endometrial cancer patients who progressed following platinum-based chemotherapy and anti-PD (L)1 immunotherapy have been implemented by Eisai, and the enrollment of 30 patients was completed. In March 2025, Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) announced that the first patient has been dosed in its Phase II combination trial of PIKTOR, which is FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel. The trial is the most advanced of its kind to investigate a novel approach of dual PI3Kɑ-mTORC1/2 inhibition targeting cancer metabolism in patients with endometrial cancer. In February 2025, Acrivon Therapeutics announced that the FDA had granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer. In December 2024, Repare Therapeutics Inc. reported positive data from its MYTHIC Phase I gynecologic expansion clinical trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) at the recommended Phase II dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. In December 2024, IDEAYA Biosciences, Inc. announced that it has dosed the first patient in the IDEAYA-sponsored Phase I trial evaluating the combination of IDE161, the company's investigational, potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in endometrial cancer patients with high microsatellite instability (MSI-high) and microsatellite stable(MSS). Request a sample and discover the recent advances in endometrial cancer drugs @ Endometrial Cancer Pipeline Report The endometrial cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage endometrial cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the endometrial cancer clinical trial landscape. Endometrial Cancer Overview Endometrial cancer, which arises from the uterus's inner lining (the endometrium), is the most common gynecologic cancer in developed countries, with its occurrence steadily increasing. This rise is linked to factors like aging populations and growing obesity rates. Most diagnoses occur in postmenopausal women, with abnormal uterine bleeding being the most frequent symptom. Because this symptom often prompts early medical evaluation, many cases are detected at an initial stage, improving treatment success. Several risk factors play a role in the development of endometrial cancer. Obesity, metabolic syndrome, and diabetes are key contributors, with obesity responsible for about 40% of cases. Reproductive history, such as early onset of menstruation, delayed menopause, never having given birth, and infertility, also raises risk. Genetic factors, especially Lynch syndrome, increase susceptibility. In contrast, combined oral contraceptives have been linked to a decreased risk. Diagnosis usually involves an endometrial biopsy, often following a transvaginal ultrasound to measure endometrial thickness. However, research suggests transvaginal ultrasound can produce false-negative results, particularly in Black women, indicating that biopsy remains the definitive diagnostic method. Surgical staging, based on the International Federation of Gynecology and Obstetrics (FIGO) criteria, is essential for assessing disease extent and planning treatment. Treatment varies by stage. Early-stage disease is generally treated with a total hysterectomy and removal of both ovaries and fallopian tubes. Additional therapies such as radiation or chemotherapy may be recommended depending on risk factors. For advanced or recurrent disease, newer treatments like immunotherapy show promise. In particular, the combination of dostarlimab (JEMPERLI) with chemotherapy has improved survival in advanced or recurrent cases. Research continues to evolve to optimize these treatment approaches and improve patient outcomes. Find out more about endometrial cancer drugs @ Endometrial Cancer Treatment A snapshot of the Pipeline Endometrial Cancer Drugs mentioned in the report: Drugs Company Phase MoA RoA Selinexor Karyopharm Therapeutics III Exportin 1 protein inhibitors Oral EG-007 Evergreen Therapeutics III Epidermal growth factor receptor antagonists Injectable Abemaciclib Eli Lilly and Company II Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors Oral Envafolimab Alphamab Oncology/Ascletis/3D Medicine II Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants Subcutaneous Sirexatamab (DKN-01) Leap Therapeutics II DKK1 protein inhibitors Intravenous NP137 NETRIS Pharma II Antibody-dependent cell cytotoxicity; T lymphocyte stimulants Intravenous COM 701 Compugen I/II Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; T lymphocyte stimulants Intravenous XMT-1660 Mersana Therapeutics I Tubulin inhibitors Intravenous Learn more about the emerging endometrial cancer therapies @ Endometrial Cancer Clinical Trials Endometrial Cancer Therapeutics Assessment The endometrial cancer pipeline report proffers an integral view of the emerging endometrial cancer therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action. Scope of the Endometrial Cancer Pipeline Report Coverage : Global : Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action : Exportin 1 protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, DKK1 protein inhibitors, Tubulin inhibitors, Epidermal growth factor receptor antagonists : Exportin 1 protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, DKK1 protein inhibitors, Tubulin inhibitors, Epidermal growth factor receptor antagonists Key Endometrial Cancer Companies : Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imva,x and others. : Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imva,x and others. Key Endometrial Cancer Pipeline Therapies: Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others. Dive deep into rich insights for new endometrial cancer treatments, visit @ Endometrial Cancer Drugs Table of Contents 1. Endometrial Cancer Pipeline Report Introduction 2. Endometrial Cancer Pipeline Report Executive Summary 3. Endometrial Cancer Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Endometrial Cancer Clinical Trial Therapeutics 6. Endometrial Cancer Pipeline: Late-Stage Products (Pre-registration) 7. Endometrial Cancer Pipeline: Late-Stage Products (Phase III) 8. Endometrial Cancer Pipeline: Mid-Stage Products (Phase II) 9. Endometrial Cancer Pipeline: Early-Stage Products (Phase I) 10. Endometrial Cancer Pipeline Therapeutics Assessment 11. Inactive Products in the Endometrial Cancer Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Endometrial Cancer Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the endometrial cancer pipeline therapeutics, reach out @ Endometrial Cancer Therapeutics Related Reports Endometrial Cancer Epidemiology Forecast Endometrial Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted endometrial cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Endometrial Cancer Market Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including GlaxoSmithKline, Merck & Co, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Incyte Corporation, among others. Advanced Endometrial Cancer Pipeline Advanced Endometrial Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced endometrial cancer companies, including Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech, Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics, Inc., Celon Pharma SA, Dragonfly Therapeutics, among others. Endometriosis Pipeline Endometriosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others. Endometriosis Pain Market Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. Endometriosis Pain Pipeline Endometriosis Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
2 hours ago
- Yahoo
WeightWatchers Returns With a Plan for the New GLP-1 World
WeightWatchers is no longer content to stew about its seemingly slender prospects in the Wegovy era. After the GLP-1 onslaught plunged the company into Chapter 11 submission in May, the dieting brand emerged from bankruptcy last week to announce it had successfully trimmed the fat from its considerable debt load, built a strategy for success moving forward, and plans to relist on the Nasdaq. READ ALSO: Bitcoin Tops $120,000 With Congress Poised to Consider Key Crypto Bills and Inflation Data and Bank Earnings Kick Off a Crucial Test for Markets It's worth remembering that the company, which rebranded as WW International in 2019, was already in trouble before a little weekly injectable came along that promised the same results as being a WeightWatchers client without the arduous processes of carefully scheduled workout classes and calorie-counted meals. The pandemic had already crushed its in-person business, and business never recovered. In 2018, the company reported annual revenue of $1.5 billion; by 2021, that had fallen to $1.2 billion, and by 2024, a measly $800 million. By May, company lawyers proclaimed in a bankruptcy hearing that an 'evolution in consumer preferences and the rapid rise of GLP-1s' made it unable to service its $1.6 billion debt load. Now? WeightWatchers wants to turn GLP-1s from poison pill to bottom line miracle drug, among other plans to rev up new revenue: The company has struck a deal with Novo Nordisk to sell weight loss drug Wegovy directly to clients on its online platform at $299 per month. WeightWatchers set the stage for such a movie in 2023 when it acquired telehealth company Sequence for $132 million. The company also plans to push into menopause treatment plans, which it says is designed to address a broader gap in healthcare. 'It is a very natural overlap. In the perimenopausal and menopausal phase, up to 70% of women experience weight gain,' newly hired Chief Medical Officer Dr. Kim Boyd told Reuters last week. The Ringer: The company will also have help from someone who knows the GLP-1 industry with great intimacy. As it emerges from bankruptcy, WeightWatchers has appointed a new board of directors — among them former Eli Lilly president Mike Mason, who helped pioneer the GLP-1 industry. 'As medical treatments like GLP-1s become more widely used, the need for trusted, comprehensive care models that combine medication with lasting lifestyle change has never been greater,' Mason said in a statement. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
